Clinical Trial Details
| Trial ID: | L0581 |
| Source ID: | JPRN-UMIN000022651 |
| Associated Drug: | Pioglitazone |
| Title: | |
| Acronym: | -- |
| Status: | Not Recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Type 2 diabetes with nonalcoholic fatty liver disease |
| Interventions: | Ipragliflozin 50 mg per day for 24 weeks<br>Pioglitazone 15-30 mg per day for 24 weeks |
| Outcome Measures: | Change from baseline in liver-to-spleen attenuation ratio (L/S ratio) by CT at week 24Changes from baseline in AST, ALT, HbA1c, fasting plasma glucose, bodyweight, abdominal visceral adipose tissue, and subcutaneous adipose tissue at week 24. |
| Sponsor/Collaborators: | Ogawa Red Cross Hospital |
| Gender: | All |
| Age: | 20years-old75years-old |
| Phases: | Not selected |
| Enrollment: | 60 |
| Study Type: | Interventional |
| Study Designs: | Parallel Randomized |
| Start Date: | 07/06/2016 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 2 April 2019 |
| Locations: | Japan |
| URL: | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026084 |
